ReviewProtein & cell2012
Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy.
Review in Protein & cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Genetically engineered senescence-resistant human mesenchymal progenitor cells promote spinal cord injury repair.Life medicine · 2026Article
- Mesenchymal stem cell therapy for end-stage liver disease: adversity and opportunity.Stem cell research & therapy · 2025Review
- Single-cell profiling identifies hair cell SLC35F1 deficiency as a signature of primate cochlear aging.Nature aging · 2025Article
- Mitochondrial sirtuins, key regulators of aging.Life medicine · 2025Review
- Human iPSC-derived self-assembled cardiac organoids for evaluating drug developmental cardiotoxicity.Life medicine · 2025Article
- Gene therapy strategies for aging intervention.Cell insight · 2025Review
- RIG-I-driven CDKN1A stabilization reinforces cellular senescence.Science China. Life sciences · 2025Article
- Human iPSC-Based Model of COPD to Investigate Disease Mechanisms, Predict SARS-COV-2 Outcome, and Test Preventive Immunotherapy.Stem cells (Dayton, Ohio) · 2024Article
- Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery.Pharmaceutics · 2023Review
- Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease.EXCLI journal · 2023Review
- Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.International journal of molecular sciences · 2022Review
- Bioprinting of a Hepatic Tissue Model Using Human-Induced Pluripotent Stem Cell-derived Hepatocytes for Drug-Induced Hepatotoxicity Evaluation.International journal of bioprinting · 2022Article
- Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models.International journal of molecular sciences · 2021Review
- Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations.Stem cell research & therapy · 2019Review
- Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review.Micromachines · 2019Review
- Liver 'organ on a chip'.Experimental cell research · 2018Review
- Nonintegrating Direct Conversion Using mRNA into Hepatocyte-Like Cells.BioMed research international · 2018Article
- Effects of Co-Culture Media on Hepatic Differentiation of hiPSC with or without HUVEC Co-Culture.International journal of molecular sciences · 2017Article
- Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells.Development (Cambridge, England) · 2017Article
- An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in the study of human hepatocytes derived from induced pluripotent stem cells (iPSC) represent new promises for liver disease study and drug discovery. Human hepatocytes or hepatocyte-like cells differentiated from iPSC recapitulate many functional properties of primary human hepatocytes and have been demonstrated as a powerful and efficient tool to model human liver metabolic diseases and facilitate drug development process. In this review, we summarize the recent progress in this field and discuss the future perspective of the application of human iPSC derived hepatocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.